pLOG

2024-03-08

U.S. Oncologists Want More Weapons for NSCLC

U.S. oncologists are not satisfied with the treatment of non-small cell lung cancer (NSCLC), expressing a desire for more treatment options, more weapons to combat different patients, more research on handling complications, and more tools to predict treatment responses.

NSCLC,

  • Short for Non-small cell lung cancer, remains an area of considerable unmet need in the medical field, according to a survey conducted by the Cancer Research Institute (CRI) and the consulting firm Harris among 250 oncologists treating NSCLC patients. Approximately 30% of respondents believe that more immunotherapy is needed for advanced NSCLC, with only 17% of physicians considering existing treatment options as quite outstanding.
  • About 88% of oncologists believe that patients with advanced NSCLC and comorbidities require more research, with approximately 45% of these patients having hypertension or lung diseases. Additionally, about two-thirds of respondents indicated that there are insufficient tools for patients with cardiovascular diseases.

Treatment Options for Patients with Poor Health Conditions?

  • Physicians also noted the need for more resources for patients with brain metastases, those of ethnic minorities, and those aged 70 and above. While chemotherapy remains part of the treatment regimen for advanced NSCLC patients, those with poorer health conditions may require gentler medications, fewer medications, or a switch to radiation therapy.

Regeneron Seeks Market Gaps

  • NSCLC is an area of focus for Regeneron, with their PD-1 inhibitor Libtayo currently being investigated for use in NSCLC alongside its established application in cutaneous squamous cell carcinoma (CSCC). The company is also evaluating the effectiveness of its EGFRxCD28 bispecific antibody in EGFR-mutated NSCLC.
  • CSCC: Cutaneous squamous cell carcinoma 
  • EGFR: Epidermal growth factor receptor

This article's content has been licensed to PatientForce™ (Media-WIND Communications: 27903403) by PharmaScan, and all intellectual property rights are shared by PatientForce™ and PharmaScan. If you have any concerns about potential infringement, please contact the relevant department of our company, and we will respond as soon as possible.